The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.
 
Rita Migliorino
Honoraria - AstraZeneca/MedImmune; Novartis Italy; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - Lilly; Pfizer; Roche
 
Lorenza Landi
Honoraria - AstraZeneca; Bayer; BRISTOL MYERS SQUIBB; Lilly; Merck; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol Myers Squibb; Lilly; Merck; Pfizer; Roche; Takeda
 
Domenico Galetta
Speakers' Bureau - Astra Zeneca Italia; BMS Italy; Lilly; MSD Oncology; Roche
 
Daniela Soregaroli
No Relationships to Disclose
 
Serena Ricciardi
No Relationships to Disclose
 
Gabriele Minuti
No Relationships to Disclose
 
Michele Montrone
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; MSD Oncology; Roche
 
Ilaria Marech
No Relationships to Disclose
 
Alessandro Morabito
Consulting or Advisory Role - Boehringer Ingelheim; MSD; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Lilly; MSD; Novartis; Roche
 
Rossana Berardi
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Eisai; GlaxoSmithKline; Lilly; MSD Oncology (Inst); Novartis (Inst); Otsuka; Roche (Inst)
 
Silvia Novello
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Danilo Rocco
No Relationships to Disclose
 
Sara Pilotto
Honoraria - AstraZeneca; BMS
Consulting or Advisory Role - Amgen; Merck
Speakers' Bureau - Amgen; AstraZeneca; BMS; Lilly; Merck; Novartis; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; BMS; Roche
 
Francesca Zanelli
No Relationships to Disclose
 
Carmelo Bengala
Consulting or Advisory Role - AstraZeneca/Merck; Roche
 
Angelo Delmonte
Consulting or Advisory Role - Novartis; Takeda
Speakers' Bureau - Bristol-Myers Squibb
 
Michele Aieta
No Relationships to Disclose
 
Diego Luigi Cortinovis
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Federico Cappuzzo
Honoraria - AstraZeneca/MedImmune; Lilly; MSD Oncology; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD Oncology; pfizer; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics